Back to today’s briefing

Story perspectives

FDA Approves CRISPR Therapies; Mammoth Biosciences Innovates Delivery

2/15/2025

26 2

Summary

Story summary

CRISPR-Cas9 is transforming biotechnology, allowing for groundbreaking gene editing to combat inherited diseases. In a monumental step, the FDA approved CRISPR therapies for sickle cell disease and beta thalassemia in late 2023. Yet, delivery hurdles remain. Enter Mammoth Biosciences and their innovative NanoCas, a streamlined Cas9 version that enhances delivery to diverse body tissues.

1 of 1

Story summary

CRISPR-Cas9 is transforming biotechnology, allowing for groundbreaking gene editing to combat inherited diseases. In a monumental step, the FDA approved CRISPR therapies for sickle cell disease and beta thalassemia in late 2023. Yet, delivery hurdles remain. Enter Mammoth Biosciences and their innovative NanoCas, a streamlined Cas9 version that enhances delivery to diverse body tissues.